摘要
Multidrug resistance(MDR) is the main cause of clinical treatment failure and poor prognosis in cancer. Targeting P-glycoprotein(P-gp) has been regarded as an effective strategy to overcome MDR. In this work, we reported our preclinical studies of the triazolo[1,5-a]pyrimidine-based compound WS-716 as a highly potent, specific, and orally active P-gp inhibitor. Through direct binding to P-gp,WS-716 inhibited efflux function of P-gp and specifically reversed P-gp-mediated MDR to paclitaxel(PTX) in multiple resistant cell lines, without changing its expression or subcellular localization. WS-716 and PTX synergistically inhibited formation of colony and 3D spheroid, induced apoptosis and cell cycle arrest at G2/M phase in resistant SW620/Ad300 cells. In addition, WS-716 displayed minimal effect on the drug-metabolizing enzyme cytochrome P4503A4(CYP3A4). Importantly, WS-716 increased sensitivity of both pre-clinically and clinically derived MDR tumors to PTX in vivo with the T/C value of 29.7% in patient-derived xenograft(PDX) models. Relative to PTX treatment alone, combination of WS-716 and PTX caused no obvious adverse reactions. Taken together, our preclinical studies revealed therapeutic promise of WS-716 against MDR cancer, the promising data warrant its further development for cancer therapy.
基金
financial support from the National Natural Science Foundation of China (Nos.81973177,82103560 and 82103996)
Medical Science and Technique Foundation of Henan Province (Nos.2018020486 and SB201901101,China)
Science and Technique Foundation of Henan Province (Nos.202102310413,China)
Natural Science Foundation of Henan Province (Nos.222300420069,212300410270 and 212300410253,China)
1000 Talents Program of Central plains (No.204200510023,China)
Young and Middleaged Health and Technology Innovation Leading Talent Project of Henan Province (No.YXKC2020008,China)
Program for Science & Technology Innovation Talents in Universities of Henan Province (No.21HASTIT045,China)
State Key Laboratory of Esophageal Cancer Prevention & Treatment (No.Z2020000X,China)。
